

# BAUSCH HEALTH COMPANIES INC.

ISIN: CA0717341071 WKN: 071734107

## Overview

|                     |   |
|---------------------|---|
| 2024/10/18 08:16:31 |   |
| <b>Price</b>        | 7.361 EUR   |
| <b>Difference</b>   | <span style="color: red;">▼</span> -4.49% (-0.35) |

| General attributes |                  |
|--------------------|------------------|
| ISIN               | CA0717341071     |
| Symbol             | BHC              |
| Exchange           | Frankfurt        |
| Currency           | EUR              |
| Sector             | Other            |
| Security type      | Stock            |
| Market cap (m)     | 2,766 EUR        |
| Benchmark          | S&P/TSX 60 INDEX |

| Market data       |             |
|-------------------|-------------|
| Bid (Bid size)    | -           |
| Ask (Ask size)    | -           |
| Open              | 7.361 EUR   |
| High              | 7.361 EUR   |
| Low               | 7.361 EUR   |
| Close (prev. day) | 7.707 EUR   |
| VWAP              | 7.18151 EUR |
| Volume (pcs)      | 0           |
| Trading volume    | 0.00        |
| Number of trades  | 2           |
| Last size         | 0           |

| Futures and Options |    |
|---------------------|----|
| Related Futures     | 14 |
| Related Options     | -  |

| PDF Downloads                                |                   |
|--|-------------------|
| Company report: BAUSCH HEALTH COMPANIES INC. | <a href="#">📄</a> |

5Y



Information about previous performance does not guarantee future performance.  
**Source:** FactSet

### Recent research

| on sector  |  |                       |                   |
|------------|--|-----------------------|-------------------|
| Date       |  | Headline              | Download          |
| 2024/09/27 |  | Global Equity Ratings | <a href="#">📄</a> |
| 2024/09/11 |  | Global Equity Ratings | <a href="#">📄</a> |
| 2024/09/05 |  | Global Equity Ratings | <a href="#">📄</a> |
| 2024/08/12 |  | Global Equity Ratings | <a href="#">📄</a> |
| 2024/07/24 |  | Global Equity Ratings | <a href="#">📄</a> |

## Details

2024/10/18 08:16:31

## Price

7.361 EUR

Difference ▼ -4.49% (-0.35)

## General attributes

|                |                  |
|----------------|------------------|
| ISIN           | CA0717341071     |
| Symbol         | BHC              |
| Exchange       | Frankfurt        |
| Currency       | EUR              |
| Sector         | Other            |
| Security type  | Stock            |
| Market cap (m) | 2,766 EUR        |
| Benchmark      | S&P/TSX 60 INDEX |

## Market data

|                   |             |
|-------------------|-------------|
| Bid (Bid size)    | -           |
| Ask (Ask size)    | -           |
| Open              | 7.361 EUR   |
| High              | 7.361 EUR   |
| Low               | 7.361 EUR   |
| Close (prev. day) | 7.707 EUR   |
| VWAP              | 7.18151 EUR |
| Volume (pcs)      | 0           |
| Trading volume    | 0.00        |
| Number of trades  | 2           |
| Last size         | 0           |

## Performance and Risk

|             | 6m     | 1Y     | 3Y      |
|-------------|--------|--------|---------|
| Perf (%)    | -8.55% | +2.38% | -69.78% |
| Perf (abs.) | -0.69  | +0.17  | -17.00  |
| Beta        | 1.37   | 1.69   | 1.77    |
| Volatility  | 65.49  | 56.28  | 74.83   |

5Y



Information about previous performance does not guarantee future performance.  
Source: FactSet

## Price data

|   |                        |
|---|------------------------|
| Ø price 5 days   Ø volume 5 days (pcs.)     | 7.508 EUR (806)        |
| Ø price 30 days   Ø volume 30 days (pcs.)   | 6.945 EUR (214)        |
| Ø price 100 days   Ø volume 100 days (pcs.) | 6.117 EUR (168)        |
| Ø price 250 days   Ø volume 250 days (pcs.) | 6.861 EUR (118)        |
| YTD High   date                             | 9.817 EUR (2024/03/28) |
| YTD Low   date                              | 4.690 EUR (2024/08/08) |
| 52 Weeks High   date                        | 9.817 EUR (2024/03/28) |
| 52 Weeks Low   date                         | 4.690 EUR (2024/08/08) |

## Arbitrage views

| Exchange <span>⊕</span> | Date       | Time  | Price     | Trading volume (mio.) | Number of trades |
|-------------------------|------------|-------|-----------|-----------------------|------------------|
| Tradegate               | 2024/10/18 | 22:02 | 7.516 EUR | 0.00                  | 1                |
| Toronto Stock Exchange  | 2024/10/18 | 22:00 | 11.26 CAD | 2.54                  | 1,057            |
| Stuttgart               | 2024/10/18 | 21:31 | 7.492 EUR | 0.00                  | 5                |
| SIX Swiss Exchange      | 2019/06/28 | 17:35 | 24.11 CHF | 0.00                  | 1                |
| NYSE                    | 2024/10/18 | 22:00 | 8.16 USD  | 12.08                 | 10,881           |

|             |            |       |       |     |      |   |
|-------------|------------|-------|-------|-----|------|---|
|             | 18         |       |       |     |      |   |
| Munich      | 2024/10/18 | 08:01 | 7.52  | EUR | 0.00 | 2 |
| Frankfurt   | 2024/10/18 | 08:16 | 7.361 | EUR | 0.00 | 2 |
| Duesseldorf | 2024/10/18 | 08:10 | 7.359 | EUR | 0.00 | 3 |
| Berlin      | 2024/10/18 | 08:01 | 7.361 | EUR | 0.00 | 2 |

## Company profile

### Company Logo



### Contact Details

BAUSCH HEALTH COS. INC.

--

2150 St. Elzéar Boulevard West - H7L 4A8  
Laval

Telefon: +1-514-744-6792

Fax: +

E-mail: -

### PDF Downloads

Company report: BAUSCH HEALTH  
COMPANIES INC.



### Company Profile

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

### Members of Management Board

|                      |                               |
|----------------------|-------------------------------|
| Thomas Appio         | Chairman of Managing Board    |
| Tage Ramakrishna     | Member of Executive Committee |
| Cees Heiman          | Member of Executive Committee |
| Fernando Zarate      | Member of Executive Committee |
| Graham Jackson       | Member of Executive Committee |
| Jeff Hartness        | Member of Executive Committee |
| Kathleen Fitzpatrick | Member of Executive Committee |
| Mirza Dautbegovic    | Member of Executive Committee |
| Seana Carson         | Member of Executive Committee |
| Tom Vadaketh         | Member of Executive Committee |

### Board of directors

|                  |                               |
|------------------|-------------------------------|
| John Paulson     | Chairman of Supervisory Board |
| Amy Wechsler     | Member of Supervisory Board   |
| Richard Mulligan | Member of Supervisory Board   |
| Brett Icahn      | Member of Supervisory Board   |
| Christian Garcia | Member of Supervisory Board   |
| Frank Lee        | Member of Supervisory Board   |
| Robert Power     | Member of Supervisory Board   |
| Sarah Kavanagh   | Member of Supervisory Board   |
| Steven Miller    | Member of Supervisory Board   |